ALX Oncology Holdings (Nasdaq: ALXO) reported a second quarter of 2026 in which the company executed on the strategic shift it announced in mid-2025: clinical-stage focus narrowed to a single lead program, evorpacept in HER2-positive metastatic breast cancer, with a second asset, ALX2004, in early dose-escalation. Reported on August 6, 2026, the quarter delivered a net loss of $18.0 million, down from $25.9 million a year earlier, on R&D spend of $13.1 million, down from $18.0 million, as the cost base contracted in line with the narrowed pipeline. Cash, cash equivalents and investments stood at $153.4 million at June 30, 2026, up from $48.3 million at year-end 2025 after a $140.4 million February 2026 offering, with the runway described as sufficient into the first half of 2028. The topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast trial remains the load-bearing equity event, currently expected in mid-2027. The equity, at $2.01 per share as of mid-August 2026, sits well below its 52-week high of $2.66 and well above its 52-week low of $0.617, and the market appears to be pricing the readout risk against the cash cushion. A single-arm trial in HER2-positive metastatic breast cancer, with a CD47-expression biomarker overlay validated in earlier gastric cancer work, is the company and the market are now watching.
The thesis, in our reading, is that the equity has re-rated off the 2025 ASPEN-03 and ASPEN-04 failures because management narrowed the program to the indication where the evorpacept mechanism has the strongest signal. The Phase 1b/2 zanidatamab combination in HER2-positive breast cancer produced, at the May 2026 ESMO Breast Cancer meeting, an exploratory analysis in which 5 of 5 centrally confirmed HER2-positive (ccHER2-positive) patients with high CD47 expression responded, with median progression-free survival of 22.1 months in that very small subset. Read in isolation, the n=5 figure is not a registrational dataset. Read against the same company's prior gastric cancer work, where the 65.0% response rate and 25.5-month duration of response in the retained-HER2-positive CD47-high subgroup formed the basis for the ASPEN-09-Breast biomarker-driven redesign, the breast cancer data reinforce a coherent biological narrative: evorpacept, when paired with a HER2-targeted antibody and selected for high CD47 expression, drives durable responses in heavily pre-treated patients. The market, in our view, is debating whether the ASPEN-09-Breast single-arm 80-patient readout can replicate this signal at a scale that supports an accelerated approval pathway, or whether a randomized Phase 3 is required, which the FDA's 2023 oncology guidance on accelerated approval suggests is the regulator's preferred route.
The single load-bearing risk, in our view, is the gap between the biomarker-defined subgroup signal and the broader enrolled population. The ASPEN-09-Breast trial, after its August 2025 amendment, is a single-arm study evaluated by CD47 expression, with the company reading high CD47 expression as the predictive biomarker for response. If the 80-patient dataset in mid-2027 shows a response rate that is directionally positive but below the level the FDA typically associates with accelerated approval in HER2-positive metastatic breast cancer, the equity compresses back toward its 52-week low, and management is forced to initiate a randomized confirmatory study that the current cash runway may not fully cover. The dilution already absorbed is substantial: the share count rose from 54.4 million at year-end 2025 to 138.2 million at June 30, 2026, a 154% increase that reflects the February 2026 offering and pre-funded warrant exercises. A second dilutive round before the readout cannot be ruled out. The falsifiable clock is the mid-2027 ASPEN-09-Breast topline: if that readout produces a confirmed response rate in the high-CD47 subgroup at or above 50%, with median duration of response of 12 months or more, the equity re-rates materially; if it lands at or below the 26% benchmark of the historical trastuzumab-plus-chemotherapy control, the biomarker hypothesis fails and the equity compresses.